Related Experiment Video
Updated: Oct 7, 2025

A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology
Published on: February 7, 2015
Effects of Long-term Antiepileptic Therapy on Carotid Artery Intima- Media Thickness
Vipul U Kolekar1, Seema P Sindgikar1, Raghuraj Uppoor2
1Department of Paediatrics, K.S. Hegde Medical Academy, Nitte (Deemed to be University), Mangaluru, Karnataka, India.
Insights
Children on long-term antiepileptic drugs (AEDs) like valproate, phenytoin, and levetiracetam show increased carotid artery intima-media thickness (CIMT). This suggests potential atherosclerotic changes, necessitating close monitoring for cardiovascular risks.
Area of Science:
- Pediatrics
- Neurology
- Cardiology
Background:
- Common first-line antiepileptic drugs (AEDs) in children include valproate, phenytoin, and levetiracetam.
- These AEDs are associated with side effects such as obesity, atherosclerosis, and metabolic syndrome.
- Long-term AED therapy in children warrants investigation into potential cardiovascular impacts.
Purpose of the Study:
- To evaluate changes in carotid artery intima-media thickness (CIMT) in epileptic children on long-term AED monotherapy.
- To correlate CIMT changes with lipid profiles in these pediatric patients.
- To assess the early atherosclerotic burden associated with common AEDs.
Main Methods:
- A case-control study involving 84 children (1-18 years) on valproate, phenytoin, or levetiracetam monotherapy for ≥6 months.
- Carotid artery intima-media thickness (CIMT) measured using B-mode ultrasonography.
- Lipid profiles analyzed, with statistical analysis using ANOVA and Pearson correlation.
Main Results:
- No significant difference in Body Mass Index (BMI) between epileptic children and controls.
- Significantly higher mean CIMT values observed in children on valproate, phenytoin, and levetiracetam compared to controls.
- Significant correlations found between CIMT and total cholesterol, triglycerides, LDL, and VLDL levels.
Conclusions:
- Long-term monotherapy with valproate, phenytoin, and levetiracetam is associated with significantly abnormal CIMT in children.
- Elevated CIMT suggests potential atherosclerotic changes in children on these AEDs.
- Close follow-up is recommended to mitigate cardiovascular and cerebrovascular risks in these patients.
Background:
Common first-line antiepileptic drugs (AEDs) used in children are valproate, phenytoin, and levetiracetam. Many side effects for these AEDs are reported including obesity, atherosclerosis, and metabolic syndrome. The aim of our study was to evaluate changes in carotid artery intima-media thickness (CIMT) in epileptic children and to correlate with lipid profile of those who are on long-term antiepileptic therapy.
Materials And Methods:
This case-control study was done over 18 months in department of pediatrics. Sample size was 84 with equal number of cases and controls. Epileptic children between 1 and 18 years of age receiving monotherapy with valproate, phenytoin, or levetiracetam for at least 6 months were included in the study. Measurement of CIMT was done by B mode ultrasonography. Lipid profile was analyzed. Statistical analysis was performed using one-way analysis of variance (ANOVA) test and Pearson correlation.
Results:
Among 42 cases of epilepsy, 30 were on valproate, 9 on phenytoin, and 3 on levetiracetam monotherapy. No significant difference was noted in body mass index (BMI) among children receiving AED compared with that of controls (P = 0.82). Mean value for CIMT was significantly higher among valproate (0.43 ± 0.04, P ≤ 0.001), phenytoin (0.44 ± 0.04, P ≤ 0.001), and levetiracetam group (0.43 ± 0.03, P = 0.01) compared to controls (0.39 ± 0.01). Significant correlation was noted between CIMT and total cholesterol (P = 0.034), triglyceride (P = 0.011), low-density lipoprotein (P = 0.008), and very low-density lipoprotein (P = 0.011).
Conclusion:
Children on long-term monotherapy with valproate, phenytoin, and levetiracetam have significantly abnormal CIMT. This might be associated with atherosclerotic changes, and these children may require close follow-up to prevent cardiovascular and cerebrovascular risks.
More Related Videos
06:04Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
11:00A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
Published on: June 22, 2010
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Aneurysm III: Interprofessional Care
Atherosclerosis I: Introduction